NAUTILUS BIOTECHNOLOGY INC's ticker is NAUT and the CUSIP is 63909J108. A total of 87 filers reported holding NAUTILUS BIOTECHNOLOGY INC in Q3 2022. The put-call ratio across all filers is - and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $79,616 | -15.3% | 25,195 | +3.7% | 0.00% | 0.0% |
| Q2 2023 | $94,037 | +47.6% | 24,299 | +5.6% | 0.00% | – |
| Q1 2023 | $63,727 | +57.0% | 23,006 | +2.0% | 0.00% | – |
| Q4 2022 | $40,585 | -15.4% | 22,547 | -0.4% | 0.00% | – |
| Q3 2022 | $48,000 | -20.0% | 22,629 | +1.4% | 0.00% | – |
| Q2 2022 | $60,000 | – | 22,309 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| AH Equity Partners Bio II, L.L.C. | 16,298,006 | $43,842,000 | 30.79% |
| Madrona Venture Group, LLC | 6,020,770 | $16,196,000 | 7.52% |
| AH Equity Partners LSV II, L.L.C. | 1,355,911 | $3,647,000 | 3.82% |
| Ally Bridge Group (NY) LLC | 1,080,566 | $2,907,000 | 2.65% |
| Tikvah Management LLC | 1,488,895 | $4,005,000 | 1.73% |
| ArchPoint Investors | 1,449,551 | $3,899,000 | 1.54% |
| Perceptive Advisors | 9,111,151 | $24,508,000 | 0.77% |
| Bain Capital Life Sciences Investors, LLC | 2,000,000 | $5,380,000 | 0.63% |
| CROWN ADVISORS MANAGEMENT, INC. | 250,000 | $672,000 | 0.62% |
| Affinity Asset Advisors, LLC | 466,607 | $1,255,000 | 0.53% |